Gilead Posts Solid Revenue in Q2

Gilead Sciences cites strong growth in its HIV and oncology portfolios during Q2 2024.Key PointsRevenue of $7.0 billion, up 6$2.01.Management maintained full-year guidance for product sales.Gilead Sciences (GILD -3.23%), the biopharmaceutical giant known for its HIV, liver disease, and oncology treatments, announced its second quarter 2024 earnings on Aug. 8. The company reported revenue of $7.0 billion, reflecting a solid performance, particularly in its core HIV ...